运用免疫组织化学技术评估甲状腺髓样癌样本中PD-L1抗原的表达。
Evaluation of PD-L1 antigen expression using immunohistochemistry technique in medullary thyroid carcinoma samples.
作者信息
Karkheiran Behnaz, Jahanbin Behnaz, Shahverdi Golnoosh, Soleimani Vahid
机构信息
Cancer Institute, Tehran University of Medical Sciences Tehran, Iran.
Cancer Institute, Assistant Professor of Pathology, Tehran University of Medical Sciences Tehran, Iran.
出版信息
Int J Physiol Pathophysiol Pharmacol. 2023 Feb 15;15(1):12-20. eCollection 2023.
BACKGROUND
Markers related to the mechanism of tumoral cell escape from the immune system have received more attention. The PD-L1 molecule encoded by the "CD274" gene binds to T lymphocytes and can inhibit these cells. Therefore, increasing the expression of this marker on inflammatory or tumor cells can indicate tumor progression invasiveness and long-term consequences. The present study aimed to determine the expression of the PD-L1 marker in thyroid medullary tumors and to evaluate its role in predicting long-term outcomes after cancer.
METHODS
This retrospective longitudinal study was performed on pathology samples of patients with medullary thyroid carcinoma referred to the Cancer Institute of Imam Khomeini Hospital from 2015 to 2020. Slides related to medullary thyroid tumors were examined. A tissue microarray was used to evaluate the immunohistochemistry of PD-L1. Patients were followed up to assess the occurrence of recurrence. Out of 207 patients evaluated in the present study, histopathological information of 144 patients was available.
RESULTS
The expression rate of PD-L1 in our community was 14.6% in lymphocyte cells, 35.4% in tumor cells, and 12.5% in both cells. The presence of metastasis at the time of diagnosis was reported in 35 cases (72.9%), and the occurrence of tumor recurrence was reported in 38 cases (79.2%). There was no relationship between the expression of this marker and the sex and age of patients. In addition, PD-L1 expression was unrelated to the two main characteristics of this cancer, namely tumor size and its focality. The presentation of tumor PD (L1) (but not lymphocytic) was a prognostic marker for synchronous metastasis at cancer diagnosis but could not predict tumor recurrence.
CONCLUSION
PD-L1 tumor marker expression is predictable in 14.6% of lymphocyte cells, 35.4% of tumor cells, and 12.5% in the selected Iranian population with medullary thyroid cancer. The expression of this marker is not related to the morphological characteristics of the tumor, such as tumor size or focality.
背景
与肿瘤细胞逃避免疫系统机制相关的标志物受到了更多关注。由“CD274”基因编码的PD-L1分子与T淋巴细胞结合并可抑制这些细胞。因此，炎症或肿瘤细胞上该标志物表达的增加可提示肿瘤进展、侵袭性及长期后果。本研究旨在确定PD-L1标志物在甲状腺髓样肿瘤中的表达，并评估其在预测癌症后长期预后中的作用。
方法
本回顾性纵向研究对2015年至2020年转诊至伊玛目霍梅尼医院癌症研究所的甲状腺髓样癌患者的病理样本进行。检查了与甲状腺髓样肿瘤相关的切片。使用组织芯片评估PD-L1的免疫组化。对患者进行随访以评估复发情况。在本研究评估的207例患者中，有144例患者的组织病理学信息可用。
结果
在我们的研究群体中，PD-L1在淋巴细胞中的表达率为14.6%，在肿瘤细胞中的表达率为35.4%，在两种细胞中的表达率为12.5%。诊断时报告有转移的病例有35例（72.9%），报告有肿瘤复发的病例有38例（79.2%）。该标志物的表达与患者的性别和年龄无关。此外，PD-L1表达与该癌症的两个主要特征，即肿瘤大小及其局灶性无关。肿瘤PD（L1）（而非淋巴细胞）的表达是癌症诊断时同步转移的预后标志物，但无法预测肿瘤复发。
结论
在选定的伊朗甲状腺髓样癌人群中，PD-L1肿瘤标志物在14.6%的淋巴细胞、35.4%的肿瘤细胞以及12.5%的细胞中表达可预测。该标志物的表达与肿瘤的形态学特征，如肿瘤大小或局灶性无关。
Zotero 插件